Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML
- PMID: 33157042
- DOI: 10.1016/j.stem.2020.10.007
Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML
Abstract
Most patients with AML succumb to chemoresistant leukemia stem cells (LSCs), which persist and reinitiate disease years after clinical remission. In this issue of Cell Stem Cell, Jones et al. (2020) identify a therapeutically targetable mechanism of resistance to venetoclax in relapsed and refractory AML LSCs mediated by nicotinamide metabolism.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests R.M. serves on the Board of Directors of BeyondSpring Inc., is a member of the Scientific Advisory Boards for Kodikaz Therapeutic Solutions, Coherus Biosciences, and Zenshine Pharmaceuticals, and is an inventor on multiple patients related to CD47 cancer immunotherapy licensed to Gilead.
Comment on
-
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4. doi: 10.1016/j.stem.2020.07.021. Epub 2020 Aug 20. Cell Stem Cell. 2020. PMID: 32822582 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
